دورية أكاديمية
أعرض في EDS

Effect of tyrosine kinase inhibitor sunitinib on tissue repair at tooth extraction sites.

التفاصيل البيبلوغرافية
العنوان: Effect of tyrosine kinase inhibitor sunitinib on tissue repair at tooth extraction sites.
المؤلفون: Ratzkowski B; School of Health and Life Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil., Koth VS; School of Health and Life Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil., Azambuja AA; Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil., Salum FG; School of Health and Life Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil., de Figueiredo MAZ; School of Health and Life Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil., Cherubini K; School of Health and Life Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
المصدر: Oral diseases [Oral Dis] 2023 Apr; Vol. 29 (3), pp. 1070-1079. Date of Electronic Publication: 2021 Nov 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Munksgaard Country of Publication: Denmark NLM ID: 9508565 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1601-0825 (Electronic) Linking ISSN: 1354523X NLM ISO Abbreviation: Oral Dis
أسماء مطبوعة: Publication: 2001- : Copenhagen, Denmark : Munksgaard
Original Publication: Houndmills, Basingstoke, Hampshire, UK : Stockton Press, c1995-
مواضيع طبية MeSH: Bone Density Conservation Agents*/pharmacology , Bisphosphonate-Associated Osteonecrosis of the Jaw*/pathology, Rats ; Animals ; Zoledronic Acid ; Sunitinib ; Tyrosine Kinase Inhibitors ; Rats, Wistar ; Diphosphonates/pharmacology ; Tooth Extraction
مستخلص: Background: Both zoledronic acid, a potent bisphosphonate, and the antiangiogenic drug sunitinib are included in anticancer protocols and have also been associated with jaw osteonecrosis. Our aim was to compare the effect of these drugs on tissue repair at tooth extraction sites.
Methods: Wistar rats were allocated into four groups: (1) sunitinib; (2) sunitinib/zoledronic acid; (3) zoledronic acid; (4) control group. The animals underwent tooth extractions and maxillae were macro- and microscopically analyzed.
Results: On macroscopic evaluation, the zoledronic acid group showed a significantly higher frequency of oral mucosal lesion; lesions in the sunitinib/zoledronic acid group were larger, albeit not significantly so. The sunitinib/zoledronic acid group had significantly less epithelium than the zoledronic acid and control group, but showed no significant difference compared to the sunitinib group. The sunitinib/zoledronic acid and zoledronic acid groups did not differ from each other, but had significantly less connective tissue and more non-vital bone and microbial colonies than sunitinib and control groups, whereas these latter two groups did not significantly differ from each other. Vital bone and inflammatory infiltrate did not significantly differ between groups.
Conclusion: Sunitinib alone is not associated with non-vital bone, whereas the sunitinib/zoledronic acid combination and zoledronic acid alone are.
(© 2021 Wiley Periodicals LLC.)
References: Abel Mahedi Mohamed, H., Nielsen, C. E. N., & Schiodt, M. (2018). Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 125, 157-163. https://doi.org/10.1016/j.oooo.2017.10.010.
Abuohashish, H., Al-Mahalawy, H., Zakaria, O., Marei, H., Abdelhady, A., AlKindi, M., & Al-Jandan, B. (2019). Delayed healing of tooth extraction sockets after vascular endothelial growth factor inhibition by Bevacizumab. Journal of Oral and Maxillofacial Surgery, 77, 1975-1981. https://doi.org/10.1016/j.joms.2019.04.003.
Amenábar, J. M., Martins, G. B., Cherubini, K., & Figueiredo, M. A. Z. (2006). Comparison between semi-automated segmentation and manual point-counting methods for quantitative analysis of histological sections. Journal of Oral Science, 48, 139-143. https://doi.org/10.2334/josnusd.48.139.
Bacci, C., Lucchiari, N., Valente, M., Della Barbera, M., Frigo, A. C., & Berengo, M. (2011). Intra-oral bone harvesting: Two methods compared using histological and histomorphometric assessments. Clinical Oral Implants Research, 22, 600-605. https://doi.org/10.1111/j.1600-0501.2010.02022.x.
Berti-Couto, S. A., Vasconcelos, A. C. U., Iglesias, J. E., Figueiredo, M. A. Z., Salum, F. G., & Cherubini, K. (2014). Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: A study in Wistar rats. Head and Neck, 36, 84-93. https://doi.org/10.1002/hed.23260.
Beuselinck, B., Wolter, P., Karadimou, A., Elaidi, R., Dumez, H., Rogiers, A., Van Cann, T., Willems, L., Body, J-j, Berkers, J., Van Poppel, H., Lerut, E., Debruyne, P., Paridaens, R., & Schöffski, P. (2012). Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. British Journal of Cancer, 107, 1665-1671. https://doi.org/10.1038/bjc.2012.385.
Boff, R. C., Salum, F. G., Figueiredo, M. A., & Cherubini, K. (2014). Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws. Archives of Oral Biology, 59, 790-799. https://doi.org/10.1016/j.archoralbio.2014.05.002.
Bozas, G., Roy, A., Ramasamy, V., & Maraveyas, A. (2010). Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie, 33, 321-323. https://doi.org/10.1159/000313680.
Brunello, A., Saia, G., Bedogni, A., Scaglione, D., & Basso, U. (2009). Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone, 44, 173-175. https://doi.org/10.1016/j.bone.2008.08.132.
Cremers, S., Drake, M. T., Ebetino, F. H., Bilezikian, J. P., & Russell, R. G. G. (2019). Pharmacology of bisphosphonates. British Journal of Clinical Pharmacology, 85, 1052-1062. https://doi.org/10.1111/bcp.13867.
Fehm, T., Beck, V., Banys, M., Lipp, H. P., Hairass, M., Reinert, S. et al (2009). Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecologic Oncology, 112, 605-609. https://doi.org/10.1016/j.ygyno.2008.11.029.
Fleissig, Y., Regev, E., & Lehman, H. (2012). Sunitinib related osteonecrosis of jaw: A case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 113, e1-3. https://doi.org/10.1016/j.tripleo.2011.06.023.
Fusco, V., Cabras, M., Erovigni, F., Dell’Acqua, A., Arduino, P., Pentenero, M. Appendino, P., Basano, L., Ferrera, Fd, Fasciolo, A., Caka, A., & Migliario, M. (2020). A multicenter observational study on medication-related osteonecrosis of the jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy. Medicina Oral Patología Oral y Cirugia Bucal. https://doi.org/10.4317/medoral.24318.
Gordon, C. R., Rojavin, Y., Patel, M., Zins, J. E., Grana, G., Kann, B., Simons, R., & Atabek, U. (2009). A review on bevacizumab and surgical wound healing: An important warning to all surgeons. Annals of Plastic Surgery, 62, 707-709. https://doi.org/10.1097/SAP.0b013e3181828141.
Hoefert, S., & Eufinger, H. (2010). Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of three cases. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology, 110, 463-469. https://doi.org/10.1016/j.tripleo.2010.04.049.
Koch, F. P., Walter, C., Hansen, T., Jäger, E., & Wagner, W. (2011). Osteonecrosis of the jaw related to sunitinib. Oral and Maxillofacial Surgery, 15, 63-66. https://doi.org/10.1007/s10006-010-0224-y.
Kolpakova, M. E., Zubareva, A. A., Artamonova, T. D., Lisovskaya, E. K., Chefu, S. G., Yagmurov, O. D., Yaremenko, A. I., & Vlasov, T.D. (2017). Experimental model of osteonecrosis of the jaw in rats treated with zoledronic acid. British Journal of Oral and Maxillofacial Surgery, 55, 156-159. https://doi.org/10.1016/j.bjoms.2016.10.006.
Koth, V. S., Salum, F. G., de Figueiredo, M. A. Z., & Cherubini, K. (2020). Morphological and immunohistochemical features of tooth extraction sites in rats treated with alendronate, raloxifene, or strontium ranelate. Clinical Oral Investigations, 25(5), 2705-2716. https://doi.org/10.1007/s00784-020-03585-x.
Landesberg, R., Cozin, M., Cremers, S., Woo, V., Kousteni, S., Sinha, S., Garrett-Sinha, L. A., & Raghavan, S. (2008). Inhibition of oral mucosal cell wound healing by bisphosphonates. Journal of Oral and Maxillofacial Surgery, 66, 839-847. https://doi.org/10.1016/j.joms.2008.01.026.
Lugano, R., Ramachandran, M., & Dimberg, A. (2020). Tumor angiogenesis: causes, consequences, challenges and opportunities. Cellular and Molecular Life Sciences, 77, 1745-1770. https://doi.org/10.1007/s00018-019-03351-7.
Maahs, M. P., Azambuja, A. A., Campos, M. M., Salum, F. G., & Cherubini, K. (2011). Association between bisphosphonates and jaw osteonecrosis: A study in Wistar rats. Head and Neck, 33, 199-207. https://doi.org/10.1002/hed.21422.
Marx, R. E. (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery, 61, 1115-1117. https://doi.org/10.1016/S0278-2391(03)00720-1.
McGowan, K., McGowan, T., & Ivanovski, S. (2018). Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Diseases, 24, 527-536. https://doi.org/10.1111/odi.12708.
Melloni, C., Tuttolomondo, A., Anfosso, A., Calamia, C., Clemente, F. D., & Cordova, A. (2016). Sunitinib related osteonecrosis of the jaw (SURONJ): A rare occurrence? European Journal of Plastic Surgery, 39, 161-162. https://doi.org/10.1007/s00238-015-1112-3.
Mignogna, M. D., Fortuna, G., Leuci, S., Pollio, A., & Ruoppo, E. (2009). Sunitinib adverse event: Oral bullous and lichenoid mucositis. Annals of Pharmacotherapy, 43, 546-547.
Nicolatou-Galitis, O., Papadopoulou, E., Vardas, E., Kouri, M., Galiti, D., Galitis, E., Alexiou, K-E, Tsiklakis, K., Ardavanis, A., Razis, E., Athanasiadis, I., Droufakou, S., Psyrri, A., Karamouzis, M. V., Linardou, H., Daliani, D., Tzanninis, D., Sachanas, S., Laschos, K., … Ripamonti, C. I. (2020). Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Diseases, 26, 955-966. https://doi.org/10.1111/odi.13294.
Oudard, S., Beuselinck, B., Decoene, J., & Albers, P. (2011). Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treatment Reviews, 37, 178-184. https://doi.org/10.1016/j.ctrv.2010.08.005.
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M. … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. British Journal of Pharmacology, 177, 3617-3624. https://doi.org/10.1111/bph.15193.
Ramírez, L., López-Pintor, R. M., Casañas, E., de Arriba, L., & Hernández, G. (2015). New non-bisphosphonate drugs that produce osteonecrosis of the jaws. Oral Health and Preventive Dentistry, 13, 385-393.
Ravosa, M. J., Ning, J., Liu, Y., & Stack, M. S. (2011). Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Archives of Oral Biology, 56, 491-498. https://doi.org/10.1016/j.archoralbio.2010.11.003.
Schaffler, M. B., Cheung, W.-Y., Majeska, R., & Kennedy, O. (2014). Osteocytes: Master orchestrators of bone. Calcified Tissue International, 94, 5-24. https://doi.org/10.1007/s00223-013-9790-y.
Schiodt, M., Vadhan-Raj, S., Chambers, M. S., Nicolatou-Galitis, O., Politis, C., Coropciuc, R., Fedele, S., Jandial, D., Zhang, J., Ma, H., & Saunders, D. (2018). Multicenter case registry study on medication-related osteonecrosis of the jaw in advanced cancer patients. Journal of Clinical Oncology, 26, 1905-1915. https://doi.org/10.1200/JCO.2016.34.15_suppl.e21663.
Schmid, T. A., & Gore, M. E. (2016). Sunitinib in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 8, 348-371. https://doi.org/10.1177/1756287216663979.
Shuster, A., Reiser, V., Trejo, L., Ianculovici, C., Kleinman, S., & Kaplan, I. (2019). Comparison of the histopathological characteristics of osteomyelitis, medication-related osteonecrosis of the jaw, and osteoradionecrosis. International Journal of Oral and Maxillofacial Surgery, 48, 17-22. https://doi.org/10.1016/j.ijom.2018.07.002.
Sivolella, S., Lumachi, F., Stellini, E., & Favero, L. (2013). Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: An uncommon but potentially severe disease. Anticancer Research, 33, 1793-1798.
Toriumi, S., Kobayashi, A., & Uesawa, Y. (2020). Comprehensive study of the risk factors for medication-related osteonecrosis of the jaw based on the Japanese adverse drug event report database. Pharmaceuticals, 13, 1-14. https://doi.org/10.3390/ph13120467.
Tresguerres, F. G. F., Torres, J., López-Quiles, J., Hernández, G., Vega, J. A., & Tresguerres, I. F. (2020). The osteocyte: A multifunctional cell within the bone. Ann Anat, 227, 151422. https://doi.org/10.1016/j.aanat.2019.151422.
Troeltzsch, M., Woodlock, T., Kriegelstein, S., Steiner, T., Messlinger, K., & Troeltzsch, M. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. Journal of the Canadian Dental Association (Tor). 2012;78.
Vahtsevanos, K., Kyrgidis, A., Verrou, E., Katodritou, E., Triaridis, S., Andreadis, C. G., Boukovinas, I., Koloutsos, G. E., Teleioudis, Z., Kitikidou, K., Paraskevopoulos, P., Zervas, K., & Antoniades, K. (2009). Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. Journal of Clinical Oncology, 27, 5356-5362. https://doi.org/10.1200/JCO.2009.21.9584.
Yarom, N., Shapiro, C. L., Peterson, D. E., Van Poznak, C. H., Bohlke, K., Ruggiero, S. L., Migliorati, C. A., Khan, A., Morrison, A., Anderson, H., Murphy, B. A., Alston-Johnson, D., Mendes, R. A., Beadle, B. M., Jensen, S. B., & Saunders, D. P. (2019). Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. Journal of Clinical Oncology, 37, 2270-2290. https://doi.org/10.1200/JCO.19.01186.
Zhang, X., Hamadeh, I. S., Song, S., Katz, J., Moreb, J. S., Langaee, T. Y., Lesko, L. J., & Gong, Y. (2016). Osteonecrosis of the jaw in the United States food and drug administration’s adverse event reporting system (FAERS). Journal of Bone and Mineral Research, 31, 336-340. https://doi.org/10.1002/jbmr.2693.
معلومات مُعتمدة: Coordenação de Aperfeiçoamento de Pessoal de Nivel Superior (CAPES)
فهرسة مساهمة: Keywords: bisphosphonates; osteonecrosis; sunitinib; tooth extractions; wound healing
المشرفين على المادة: 6XC1PAD3KF (Zoledronic Acid)
0 (Bone Density Conservation Agents)
V99T50803M (Sunitinib)
0 (Tyrosine Kinase Inhibitors)
0 (Diphosphonates)
تواريخ الأحداث: Date Created: 20211101 Date Completed: 20230321 Latest Revision: 20231213
رمز التحديث: 20231215
DOI: 10.1111/odi.14065
PMID: 34724280
قاعدة البيانات: MEDLINE
الوصف
تدمد:1601-0825
DOI:10.1111/odi.14065